Accessibility Menu
Virax Biolabs Group logo

Virax Biolabs Group(NASDAQ) VRAX

Current Price$3.19
Market Cap$2.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-100%
5 YearN/A
1 Year-88%
1 Month-3%
Virax Biolabs Group last closing stock price
MetricPriceDate
Last closeUSD 3.192026-07-24
Virax Biolabs Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.83%USD 3.792026-07-17
1 month-3.33%USD 3.302026-06-24
3 month-20.05%USD 3.992026-04-24
Year to date-63.1%USD 8.652025-12-31
1 year-87.61%USD 25.752025-07-24
3 year-96.75%USD 98.102023-07-25
Since inception-99.92%USD 4,550.002022-07-21

Virax Biolabs Group Financials at a Glance

Market Cap

$2.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$18.75K

Net Income (TTM)

-$11.08M

EPS (TTM)

-$16.91

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$3.19

Volume

86,392.975

Open

$3.17

Previous Close

$3.19

Daily Range

$3.11 - $3.19

52-Week Range

$2.50 - $25.75

Estimated Earnings Date

Jul 1, 2026

VRAX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Virax Biolabs Group

Virax Biolabs Group Limited is a biotechnology firm focused on the sale, distribution, and promotion of diagnostic testing kits, medical technology, and personal protective equipment (PPE). The company aims to address risks associated with viral illnesses through its innovative product offerings.

Products and Services
  • Diagnostic tools under the ViraxClear brand, including rapid antibody assays and PCR tests
  • Medical technology and PPE products marketed under the ViraxCare brand
  • E-commerce platform for easy access to ViraxClear and ViraxCare product lines
Growth Outlook
  • Expansion into international markets, including Europe and South America
  • Increased demand for diagnostic testing amid ongoing health concerns
  • Strategic partnerships to enhance product offerings and market reach
Financial Highlights
  • Recent quarterly revenue of 76,500, showing potential for growth
  • Cash and cash equivalents of 5,107,882, providing liquidity for operations
  • Current ratio of 11.35, indicating strong short-term financial health
Virax Biolabs Group Limited operates in a critical sector, providing essential tools for the diagnosis and management of viral illnesses. The company's diverse product range, including diagnostic kits and PPE, positions it well to meet the growing global demand for health solutions. With a strong cash position and a favorable current ratio, the company is equipped to navigate challenges and capitalize on opportunities in the biotechnology industry. The ongoing expansion into international markets and strategic partnerships further enhance its growth potential, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Jun 26, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

26

CEO

James Foster

Website

www.viraxbiolabs.com

Headquarters

Lanarkshire, SC ML1 5UH, GB

VRAX Financials

Key Financial Metrics (TTM)

Gross Margin

61.90%

Operating Margin

-51515.17%

Net Income Margin

-40439.10%

Return on Equity

-77.95%

Return on Capital

-80.08%

Return on Assets

-60.35%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

797.00K

Volume

86.39K

Avg. Volume

2.22M

Financials (TTM)

Gross Profit

-$45.38K

Operating Income

-$12.56M

EBITDA

-$11.95M

Operating Cash Flow

-$9.35M

Capital Expenditure

-$859.72K

Free Cash Flow

-$10.21M

Cash & ST Invst.

$6.52M

Total Debt

$414.39K

Virax Biolabs Group Performance Analysis

Virax Biolabs Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 8,561N/A
20242024-03-31USD 156,4191727.1%
20252025-03-31USD 6,331-96.0%
20262026-03-31USD 12,42396.2%
Virax Biolabs Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-30-93.8%
Q42025-03-31-72.2%
Q22025-09-3016.7%
Q42026-03-31572.6%
Virax Biolabs Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -128.35241.7%
20242024-03-31USD -83.90-34.6%
20252025-03-31USD -40.62-51.6%
20262026-03-31USD -12.64-68.9%
Virax Biolabs Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-09-3048.0%
Q42025-03-3114.6%
Q22025-09-3035.5%
Q42026-03-3163.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$10.82K

-86.5%

Gross Profit

$223.10K

+456.8%

Gross Margin

20.63%

N/A

Market Cap

$2.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$97.78K

N/A

Employees

26

N/A

Net Income

-$2.68M

+29.8%

EBITDA

-$3.68M

+1.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$6.52M

+81.6%

Total Debt

$414.39K

+84.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$48.04K

-20.4%

Long Term Debt

$304.81K

+72.8%

Short Term Debt

$109.58K

+128.5%

Return on Assets

-60.35%

N/A

Return on Invested Capital

-83.77%

N/A

Free Cash Flow

-$1.98M

+39.2%

Operating Cash Flow

-$1.86M

+33.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARTLArtelo Biosciences, Inc.
$1.02-3.77%
ELABPMGC Holdings Inc.
$0.90-5.15%
NCELNewcelX Ltd.
$3.76-1.18%
GTBPGT Biopharma, Inc.
$0.32-3.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
FFord Motor Company
$14.37+0.02%

Questions About VRAX

What is the current price of Virax Biolabs Group?

Virax Biolabs Group is trading at $3.19 per share.

What is the 52-week range for Virax Biolabs Group?

Over the past 52 weeks, Virax Biolabs Group has traded between $2.50 and $25.75.

How much debt does Virax Biolabs Group have?

As of the most recent reporting period, Virax Biolabs Group reported total debt of $414.39K.

How much cash does Virax Biolabs Group have on hand?

Virax Biolabs Group reported $6.44M in cash and cash equivalents in its most recent financial results.

What is Virax Biolabs Group’s dividend yield?

Virax Biolabs Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services